Echosens and Boehringer Ingelheim have expanded their long-standing partnership to change the trajectory of metabolic dysfunction-associated steatohepatitis (MASH) by moving beyond clinical trials to focus on early detection, diagnosis, and access to care.

In combining diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps in awareness, real-world evidence, and clinical adoption.

The next phase of the partnership will raise awareness of MASH among patients, healthcare professionals, and policymakers about the urgent need for early screening and diagnosis. As well as raise awareness and access to non-invasive technologies (NITs), including scientific collaborations to generate evidence relating to NITs in the care of people living with MASH.

The companies will also encourage the adoption of streamlined care pathways by fostering collaboration across healthcare organizations and medical specialties.

FibroScan, Echosens’ non-invasive liver assessment technology, has played a critical role in Boehringer Ingelheim’s liver disease research and continues to support two ongoing Survodutide Phase III trials by screening and monitoring patients. As a non-invasive test, FibroScan acts as an alternative to liver biopsy. 

Survodutide combines GLP-1 and glucagon receptor agonists as a potential treatment for MASH and associated metabolic conditions like obesity. Survodutide is part of Boehringer Ingelheim’s research and development portfolio in the cardiovascular, renal, and metabolic disease areas. 

Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally.

Dominique Legros, CEO of Echosens, said, “This partnership reflects our ongoing commitment to support the global liver disease community by enabling smarter clinical trials and broader access to non-invasive diagnostic tools. We are proud to collaborate with Boehringer Ingelheim and welcome them into our shared mission to improve liver health outcomes.”